Over the last few months, not many topics have been discussed as much as the General Data Protection Regulation becoming effective. As the regulation has now been in practice for some time, the impact is becoming apparent.
Lung cancer is the second most common malignancy in the world, and is the leading cause of cancer deaths worldwide. In 2012 there were diagnosed more than 1,8 million new lung cancer cases and lung cancer caused more than 1.6 million deaths.
Ensuring you have instant access to your clinical trial data is stressful – you need to invest in smart e-solutions, train your teams in system(s) use, and ensure they work with the data on an ongoing basis, report on it and act when any findings are made as first results flow in. Seems like a lot of work, time and costs when compared to collecting data on various external sources, cleaning it in batches at the end of the study and resolving issues just shortly before closing the database. Why stress your clinical trial team with the additional demands?
This article is to elaborate on how “no news” during the life of a trial is bad news and what data management (among other things) can do to help when ensuring access to fast data.